APO Research
Talk to an analyst

APO RESEARCH · REPORT

Premenstrual Syndrome Medicine

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Premenstrual Syndrome Medicine Market Outlook and Growth Opportunities 2026

26 December 2025199 pages

Choose your research edition.

Industry ResearchPremenstrual Syndrome Medicine Industry Research Report 2026108 pages · $2,950 USDIndustry Growth & TrendsGlobal Premenstrual Syndrome Medicine Industry Growth and Trends Forecast to 203271 pages · $3,450 USDMarket StructureGlobal Premenstrual Syndrome Medicine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032172 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Premenstrual Syndrome Medicine Market Outlook and Growth Opportunities 2026199 pages · $4,250 USDMarket Analysis & ForecastGlobal Premenstrual Syndrome Medicine Market Analysis and Forecast 2026-2032194 pages · $4,950 USD

Market perspective

The global Premenstrual Syndrome Medicine market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Premenstrual Syndrome Medicine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Premenstrual Syndrome Medicine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Premenstrual Syndrome Medicine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Premenstrual Syndrome Medicine market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Premenstrual Syndrome Medicine market include Asarina Pharma AB and Pherin Pharmaceuticals Inc among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Premenstrual Syndrome Medicine market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Premenstrual Syndrome Medicine and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Premenstrual Syndrome Medicine sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Premenstrual Syndrome Medicine market size, projected growth trends, production technologies, key applications, and end-use industries.

Premenstrual Syndrome Medicine Segment by Company

Asarina Pharma AB

Pherin Pharmaceuticals Inc

Premenstrual Syndrome Medicine Segment by Type

PH-80PMD

Progesterone

Estrogen

Others

Premenstrual Syndrome Medicine Segment by Application

Home Care

Hospital

Clinic

Premenstrual Syndrome Medicine Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Premenstrual Syndrome Medicine status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Premenstrual Syndrome Medicine market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Premenstrual Syndrome Medicine significant trends, drivers, influence factors in global and regions.

6. To analyze Premenstrual Syndrome Medicine competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Premenstrual Syndrome Medicine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Premenstrual Syndrome Medicine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Premenstrual Syndrome Medicine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Premenstrual Syndrome Medicine market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Premenstrual Syndrome Medicine industry.

Chapter 3: Detailed analysis of Premenstrual Syndrome Medicine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Premenstrual Syndrome Medicine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Premenstrual Syndrome Medicine in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Premenstrual Syndrome Medicine Industry Trends Table 2. Premenstrual Syndrome Medicine Industry Drivers Table 3. Premenstrual Syndrome Medicine Industry Opportunities and Challenges Table 4. Premenstrual Syndrome Medicine Industry Restraints Table 5. Global Premenstrual Syndrome Medicine Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Premenstrual Syndrome Medicine Revenue Share by Company (2021-2026) Table 7. Global Premenstrual Syndrome Medicine Sales Volume by Company (W Units) & (2021-2026) Table 8. Global Premenstrual Syndrome Medicine Sales Volume Share by Company (2021-2026) Table 9. Global Premenstrual Syndrome Medicine Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Premenstrual Syndrome Medicine Company Ranking, (2024-2026) & (USD Million) Table 11. Global Premenstrual Syndrome Medicine Key Company Manufacturing Base & Headquarters Table 12. Global Premenstrual Syndrome Medicine Company, Product Type & Application Table 13. Global Premenstrual Syndrome Medicine Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Premenstrual Syndrome Medicine by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of PH-80PMD Table 18. Significant Companies of Progesterone Table 19. Significant Companies of Estrogen Table 20. Significant Companies of Others Table 21. Global Premenstrual Syndrome Medicine Sales Volume by Type 2021 VS 2025 VS 2032 (W Units) Table 22. Global Premenstrual Syndrome Medicine Sales Volume by Type (2021-2026) & (W Units) Table 23. Global Premenstrual Syndrome Medicine Sales Volume by Type (2027-2032) & (W Units) Table 24. Global Premenstrual Syndrome Medicine Sales Volume Share by Type (2021-2026) Table 25. Global Premenstrual Syndrome Medicine Sales Volume Share by Type (2027-2032) Table 26. Global Premenstrual Syndrome Medicine Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Premenstrual Syndrome Medicine Sales Value by Type (2021-2026) & (US$ Million) Table 28. Global Premenstrual Syndrome Medicine Sales Value by Type (2027-2032) & (US$ Million) Table 29. Global Premenstrual Syndrome Medicine Sales Value Share by Type (2021-2026) Table 30. Global Premenstrual Syndrome Medicine Sales Value Share by Type (2027-2032) Table 31. Significant Companies of Home Care Table 32. Significant Companies of Hospital Table 33. Significant Companies of Clinic Table 34. Global Premenstrual Syndrome Medicine Sales Volume by Application 2021 VS 2025 VS 2032 (W Units) Table 35. Global Premenstrual Syndrome Medicine Sales Volume by Application (2021-2026) & (W Units) Table 36. Global Premenstrual Syndrome Medicine Sales Volume by Application (2027-2032) & (W Units) Table 37. Global Premenstrual Syndrome Medicine Sales Volume Share by Application (2021-2026) Table 38. Global Premenstrual Syndrome Medicine Sales Volume Share by Application (2027-2032) Table 39. Global Premenstrual Syndrome Medicine Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 40. Global Premenstrual Syndrome Medicine Sales Value by Application (2021-2026) & (US$ Million) Table 41. Global Premenstrual Syndrome Medicine Sales Value by Application (2027-2032) & (US$ Million) Table 42. Global Premenstrual Syndrome Medicine Sales Value Share by Application (2021-2026) Table 43. Global Premenstrual Syndrome Medicine Sales Value Share by Application (2027-2032) Table 44. Global Premenstrual Syndrome Medicine Sales by Region: 2021 VS 2025 VS 2032 (W Units) Table 45. Global Premenstrual Syndrome Medicine Sales by Region (2021-2026) & (W Units) Table 46. Global Premenstrual Syndrome Medicine Sales Market Share by Region (2021-2026) Table 47. Global Premenstrual Syndrome Medicine Sales by Region (2027-2032) & (W Units) Table 48. Global Premenstrual Syndrome Medicine Sales Market Share by Region (2027-2032) Table 49. Global Premenstrual Syndrome Medicine Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 50. Global Premenstrual Syndrome Medicine Sales Value by Region (2021-2026) & (US$ Million) Table 51. Global Premenstrual Syndrome Medicine Sales Value Share by Region (2021-2026) Table 52. Global Premenstrual Syndrome Medicine Sales Value by Region (2027-2032) & (US$ Million) Table 53. Global Premenstrual Syndrome Medicine Sales Value Share by Region (2027-2032) Table 54. Global Premenstrual Syndrome Medicine Market Average Price (US$/Unit) by Region (2021-2026) Table 55. Global Premenstrual Syndrome Medicine Market Average Price (US$/Unit) by Region (2027-2032) Table 56. Global Premenstrual Syndrome Medicine Sales by Country: 2021 VS 2025 VS 2032 (W Units) Table 57. Global Premenstrual Syndrome Medicine Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 58. Global Premenstrual Syndrome Medicine Sales by Country (2021-2026) & (W Units) Table 59. Global Premenstrual Syndrome Medicine Sales Market Share by Country (2021-2026) Table 60. Global Premenstrual Syndrome Medicine Sales by Country (2027-2032) & (W Units) Table 61. Global Premenstrual Syndrome Medicine Sales Market Share by Country (2027-2032) Table 62. Global Premenstrual Syndrome Medicine Sales Value by Country (2021-2026) & (US$ Million) Table 63. Global Premenstrual Syndrome Medicine Sales Value Market Share by Country (2021-2026) Table 64. Global Premenstrual Syndrome Medicine Sales Value by Country (2027-2032) & (US$ Million) Table 65. Global Premenstrual Syndrome Medicine Sales Value Market Share by Country (2027-2032) Table 66. Asarina Pharma AB Company Information Table 67. Asarina Pharma AB Business Overview Table 68. Asarina Pharma AB Premenstrual Syndrome Medicine Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 69. Asarina Pharma AB Premenstrual Syndrome Medicine Product Portfolio Table 70. Asarina Pharma AB Recent Development Table 71. Pherin Pharmaceuticals Inc Company Information Table 72. Pherin Pharmaceuticals Inc Business Overview Table 73. Pherin Pharmaceuticals Inc Premenstrual Syndrome Medicine Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 74. Pherin Pharmaceuticals Inc Premenstrual Syndrome Medicine Product Portfolio Table 75. Pherin Pharmaceuticals Inc Recent Development Table 76. Key Raw Materials Table 77. Raw Materials Key Suppliers Table 78. Premenstrual Syndrome Medicine Distributors List Table 79. Premenstrual Syndrome Medicine Customers List Table 80. Research Programs/Design for This Report Table 81. Authors List of This Report Table 82. Secondary Sources Table 83. Primary Sources List of Figures Figure 1. Premenstrual Syndrome Medicine Product Image Figure 2. Global Premenstrual Syndrome Medicine Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Premenstrual Syndrome Medicine Sales Value (2021-2032) & (US$ Million) Figure 4. Global Premenstrual Syndrome Medicine Sales (2021-2032) & (W Units) Figure 5. Global Premenstrual Syndrome Medicine Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Premenstrual Syndrome Medicine Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. PH-80PMD Image Figure 10. Progesterone Image Figure 11. Estrogen Image Figure 12. Others Image Figure 13. Global Premenstrual Syndrome Medicine Sales Volume by Type (2021 VS 2025 VS 2032) & (W Units) Figure 14. Global Premenstrual Syndrome Medicine Sales Volume Share 2021 VS 2025 VS 2032 Figure 15. Global Premenstrual Syndrome Medicine Sales Volume Share by Type (2021-2032) Figure 16. Global Premenstrual Syndrome Medicine Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Premenstrual Syndrome Medicine Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global Premenstrual Syndrome Medicine Sales Value Share by Type (2021-2032) Figure 19. Home Care Image Figure 20. Hospital Image Figure 21. Clinic Image Figure 22. Global Premenstrual Syndrome Medicine Sales Volume by Application (2021 VS 2025 VS 2032) & (W Units) Figure 23. Global Premenstrual Syndrome Medicine Sales Volume Share 2021 VS 2025 VS 2032 Figure 24. Global Premenstrual Syndrome Medicine Sales Volume Share by Application (2021-2032) Figure 25. Global Premenstrual Syndrome Medicine Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 26. Global Premenstrual Syndrome Medicine Sales Value Share 2021 VS 2025 VS 2032 Figure 27. Global Premenstrual Syndrome Medicine Sales Value Share by Application (2021-2032) Figure 28. Global Premenstrual Syndrome Medicine Sales by Region: 2021 VS 2025 VS 2032 (W Units) Figure 29. Global Premenstrual Syndrome Medicine Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 30. Global Premenstrual Syndrome Medicine Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 31. Global Premenstrual Syndrome Medicine Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 32. North America Premenstrual Syndrome Medicine Sales Value (2021-2032) & (US$ Million) Figure 33. North America Premenstrual Syndrome Medicine Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Europe Premenstrual Syndrome Medicine Sales Value (2021-2032) & (US$ Million) Figure 35. Europe Premenstrual Syndrome Medicine Sales Value Share by Country (%), 2025 VS 2032 Figure 36. Asia-Pacific Premenstrual Syndrome Medicine Sales Value (2021-2032) & (US$ Million) Figure 37. Asia-Pacific Premenstrual Syndrome Medicine Sales Value Share by Country (%), 2025 VS 2032 Figure 38. South America Premenstrual Syndrome Medicine Sales Value (2021-2032) & (US$ Million) Figure 39. South America Premenstrual Syndrome Medicine Sales Value Share by Country (%), 2025 VS 2032 Figure 40. Middle East & Africa Premenstrual Syndrome Medicine Sales Value (2021-2032) & (US$ Million) Figure 41. Middle East & Africa Premenstrual Syndrome Medicine Sales Value Share by Country (%), 2025 VS 2032 Figure 42. USA Premenstrual Syndrome Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. USA Premenstrual Syndrome Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. USA Premenstrual Syndrome Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Canada Premenstrual Syndrome Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Canada Premenstrual Syndrome Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Canada Premenstrual Syndrome Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Mexico Premenstrual Syndrome Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Mexico Premenstrual Syndrome Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Mexico Premenstrual Syndrome Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Germany Premenstrual Syndrome Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Germany Premenstrual Syndrome Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Germany Premenstrual Syndrome Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. France Premenstrual Syndrome Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. France Premenstrual Syndrome Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. France Premenstrual Syndrome Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. U.K. Premenstrual Syndrome Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. U.K. Premenstrual Syndrome Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. U.K. Premenstrual Syndrome Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Italy Premenstrual Syndrome Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Italy Premenstrual Syndrome Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Italy Premenstrual Syndrome Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Spain Premenstrual Syndrome Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Spain Premenstrual Syndrome Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Spain Premenstrual Syndrome Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Russia Premenstrual Syndrome Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Russia Premenstrual Syndrome Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Russia Premenstrual Syndrome Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Netherlands Premenstrual Syndrome Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Netherlands Premenstrual Syndrome Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Netherlands Premenstrual Syndrome Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. Nordic Countries Premenstrual Syndrome Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. Nordic Countries Premenstrual Syndrome Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. Nordic Countries Premenstrual Syndrome Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. China Premenstrual Syndrome Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. China Premenstrual Syndrome Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. China Premenstrual Syndrome Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Japan Premenstrual Syndrome Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Japan Premenstrual Syndrome Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Japan Premenstrual Syndrome Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. South Korea Premenstrual Syndrome Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. South Korea Premenstrual Syndrome Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. South Korea Premenstrual Syndrome Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. India Premenstrual Syndrome Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. India Premenstrual Syndrome Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. India Premenstrual Syndrome Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Australia Premenstrual Syndrome Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Australia Premenstrual Syndrome Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Australia Premenstrual Syndrome Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Southeast Asia Premenstrual Syndrome Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Southeast Asia Premenstrual Syndrome Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Southeast Asia Premenstrual Syndrome Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Brazil Premenstrual Syndrome Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Brazil Premenstrual Syndrome Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Brazil Premenstrual Syndrome Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Argentina Premenstrual Syndrome Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Argentina Premenstrual Syndrome Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Argentina Premenstrual Syndrome Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Chile Premenstrual Syndrome Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Chile Premenstrual Syndrome Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Chile Premenstrual Syndrome Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Colombia Premenstrual Syndrome Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Colombia Premenstrual Syndrome Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Colombia Premenstrual Syndrome Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Peru Premenstrual Syndrome Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Peru Premenstrual Syndrome Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Peru Premenstrual Syndrome Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Premenstrual Syndrome Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Saudi Arabia Premenstrual Syndrome Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Saudi Arabia Premenstrual Syndrome Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Israel Premenstrual Syndrome Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Israel Arabia Premenstrual Syndrome Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Israel Arabia Premenstrual Syndrome Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. UAE Premenstrual Syndrome Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. UAE Premenstrual Syndrome Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. UAE Premenstrual Syndrome Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Turkey Premenstrual Syndrome Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Turkey Premenstrual Syndrome Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Turkey Premenstrual Syndrome Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Iran Premenstrual Syndrome Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Iran Premenstrual Syndrome Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Iran Premenstrual Syndrome Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Egypt Premenstrual Syndrome Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 124. Egypt Premenstrual Syndrome Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 125. Egypt Premenstrual Syndrome Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 126. Premenstrual Syndrome Medicine Value Chain Figure 127. Manufacturing Cost Structure Figure 128. Premenstrual Syndrome Medicine Sales Mode & Process Figure 129. Direct Comparison with Distribution Share Figure 130. Distributors Profiles Figure 131. Years Considered Figure 132. Research Process Figure 133. Key Executives Interviewed

Scope & coverage.

Types
  • PH-80PMD
  • Progesterone
  • Estrogen
  • Others
Applications
  • Home Care
  • Hospital
  • Clinic
Companies covered
  • Asarina Pharma AB
  • Pherin Pharmaceuticals Inc

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Premenstrual Syndrome Medicine Sales Value (2021-2032)
  4. 1.2.2 Global Premenstrual Syndrome Medicine Sales Volume (2021-2032)
  5. 1.2.3 Global Premenstrual Syndrome Medicine Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Premenstrual Syndrome Medicine Market Dynamics
  1. 2.1 Premenstrual Syndrome Medicine Industry Trends
  2. 2.2 Premenstrual Syndrome Medicine Industry Drivers
  3. 2.3 Premenstrual Syndrome Medicine Industry Opportunities and Challenges
  4. 2.4 Premenstrual Syndrome Medicine Industry Restraints
3 Premenstrual Syndrome Medicine Market by Company
  1. 3.1 Global Premenstrual Syndrome Medicine Company Revenue Ranking in 2025
  2. 3.2 Global Premenstrual Syndrome Medicine Revenue by Company (2021-2026)
  3. 3.3 Global Premenstrual Syndrome Medicine Sales Volume by Company (2021-2026)
  4. 3.4 Global Premenstrual Syndrome Medicine Average Price by Company (2021-2026)
  5. 3.5 Global Premenstrual Syndrome Medicine Company Ranking (2024-2026)
  6. 3.6 Global Premenstrual Syndrome Medicine Company Manufacturing Base and Headquarters
  7. 3.7 Global Premenstrual Syndrome Medicine Company Product Type and Application
  8. 3.8 Global Premenstrual Syndrome Medicine Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Premenstrual Syndrome Medicine Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Premenstrual Syndrome Medicine Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Premenstrual Syndrome Medicine Market by Type
  1. 4.1 Premenstrual Syndrome Medicine Type Introduction
  2. 4.1.1 PH-80PMD
  3. 4.1.2 Progesterone
  4. 4.1.3 Estrogen
  5. 4.1.4 Others
  6. 4.2 Global Premenstrual Syndrome Medicine Sales Volume by Type
  7. 4.2.1 Global Premenstrual Syndrome Medicine Sales Volume by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Premenstrual Syndrome Medicine Sales Volume by Type (2021-2032)
  9. 4.2.3 Global Premenstrual Syndrome Medicine Sales Volume Share by Type (2021-2032)
  10. 4.3 Global Premenstrual Syndrome Medicine Sales Value by Type
  11. 4.3.1 Global Premenstrual Syndrome Medicine Sales Value by Type (2021 VS 2025 VS 2032)
  12. 4.3.2 Global Premenstrual Syndrome Medicine Sales Value by Type (2021-2032)
  13. 4.3.3 Global Premenstrual Syndrome Medicine Sales Value Share by Type (2021-2032)
5 Premenstrual Syndrome Medicine Market by Application
  1. 5.1 Premenstrual Syndrome Medicine Application Introduction
  2. 5.1.1 Home Care
  3. 5.1.2 Hospital
  4. 5.1.3 Clinic
  5. 5.2 Global Premenstrual Syndrome Medicine Sales Volume by Application
  6. 5.2.1 Global Premenstrual Syndrome Medicine Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Premenstrual Syndrome Medicine Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Premenstrual Syndrome Medicine Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Premenstrual Syndrome Medicine Sales Value by Application
  10. 5.3.1 Global Premenstrual Syndrome Medicine Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Premenstrual Syndrome Medicine Sales Value by Application (2021-2032)
  12. 5.3.3 Global Premenstrual Syndrome Medicine Sales Value Share by Application (2021-2032)
6 Premenstrual Syndrome Medicine Regional Sales and Value Analysis
  1. 6.1 Global Premenstrual Syndrome Medicine Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Premenstrual Syndrome Medicine Sales by Region (2021-2032)
  3. 6.2.1 Global Premenstrual Syndrome Medicine Sales by Region: 2021-2026
  4. 6.2.2 Global Premenstrual Syndrome Medicine Sales by Region (2027-2032)
  5. 6.3 Global Premenstrual Syndrome Medicine Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Premenstrual Syndrome Medicine Sales Value by Region (2021-2032)
  7. 6.4.1 Global Premenstrual Syndrome Medicine Sales Value by Region: 2021-2026
  8. 6.4.2 Global Premenstrual Syndrome Medicine Sales Value by Region (2027-2032)
  9. 6.5 Global Premenstrual Syndrome Medicine Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Premenstrual Syndrome Medicine Sales Value (2021-2032)
  12. 6.6.2 North America Premenstrual Syndrome Medicine Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Premenstrual Syndrome Medicine Sales Value (2021-2032)
  15. 6.7.2 Europe Premenstrual Syndrome Medicine Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Premenstrual Syndrome Medicine Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Premenstrual Syndrome Medicine Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Premenstrual Syndrome Medicine Sales Value (2021-2032)
  21. 6.9.2 South America Premenstrual Syndrome Medicine Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Premenstrual Syndrome Medicine Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Premenstrual Syndrome Medicine Sales Value Share by Country, 2025 VS 2032
7 Premenstrual Syndrome Medicine Country-level Sales and Value Analysis
  1. 7.1 Global Premenstrual Syndrome Medicine Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Premenstrual Syndrome Medicine Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Premenstrual Syndrome Medicine Sales by Country (2021-2032)
  4. 7.3.1 Global Premenstrual Syndrome Medicine Sales by Country (2021-2026)
  5. 7.3.2 Global Premenstrual Syndrome Medicine Sales by Country (2027-2032)
  6. 7.4 Global Premenstrual Syndrome Medicine Sales Value by Country (2021-2032)
  7. 7.4.1 Global Premenstrual Syndrome Medicine Sales Value by Country (2021-2026)
  8. 7.4.2 Global Premenstrual Syndrome Medicine Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Premenstrual Syndrome Medicine Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Premenstrual Syndrome Medicine Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Premenstrual Syndrome Medicine Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Premenstrual Syndrome Medicine Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Premenstrual Syndrome Medicine Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Premenstrual Syndrome Medicine Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Premenstrual Syndrome Medicine Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Premenstrual Syndrome Medicine Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Premenstrual Syndrome Medicine Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Premenstrual Syndrome Medicine Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Premenstrual Syndrome Medicine Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Premenstrual Syndrome Medicine Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Premenstrual Syndrome Medicine Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Premenstrual Syndrome Medicine Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Premenstrual Syndrome Medicine Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Premenstrual Syndrome Medicine Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Premenstrual Syndrome Medicine Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Premenstrual Syndrome Medicine Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Premenstrual Syndrome Medicine Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Premenstrual Syndrome Medicine Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Premenstrual Syndrome Medicine Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Premenstrual Syndrome Medicine Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Premenstrual Syndrome Medicine Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Premenstrual Syndrome Medicine Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Premenstrual Syndrome Medicine Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Premenstrual Syndrome Medicine Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Premenstrual Syndrome Medicine Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Premenstrual Syndrome Medicine Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Premenstrual Syndrome Medicine Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Premenstrual Syndrome Medicine Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Premenstrual Syndrome Medicine Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Premenstrual Syndrome Medicine Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Premenstrual Syndrome Medicine Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Premenstrual Syndrome Medicine Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Premenstrual Syndrome Medicine Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Premenstrual Syndrome Medicine Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Premenstrual Syndrome Medicine Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Premenstrual Syndrome Medicine Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Premenstrual Syndrome Medicine Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Premenstrual Syndrome Medicine Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Premenstrual Syndrome Medicine Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Premenstrual Syndrome Medicine Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Premenstrual Syndrome Medicine Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Premenstrual Syndrome Medicine Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Premenstrual Syndrome Medicine Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Premenstrual Syndrome Medicine Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Premenstrual Syndrome Medicine Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Premenstrual Syndrome Medicine Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Premenstrual Syndrome Medicine Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Premenstrual Syndrome Medicine Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Premenstrual Syndrome Medicine Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Premenstrual Syndrome Medicine Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Premenstrual Syndrome Medicine Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Premenstrual Syndrome Medicine Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Premenstrual Syndrome Medicine Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Premenstrual Syndrome Medicine Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Premenstrual Syndrome Medicine Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Premenstrual Syndrome Medicine Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Premenstrual Syndrome Medicine Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Premenstrual Syndrome Medicine Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Premenstrual Syndrome Medicine Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Premenstrual Syndrome Medicine Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Premenstrual Syndrome Medicine Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Premenstrual Syndrome Medicine Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Premenstrual Syndrome Medicine Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Premenstrual Syndrome Medicine Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Premenstrual Syndrome Medicine Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Premenstrual Syndrome Medicine Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Premenstrual Syndrome Medicine Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Premenstrual Syndrome Medicine Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Premenstrual Syndrome Medicine Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Premenstrual Syndrome Medicine Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Premenstrual Syndrome Medicine Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Premenstrual Syndrome Medicine Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Premenstrual Syndrome Medicine Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Premenstrual Syndrome Medicine Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Premenstrual Syndrome Medicine Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Premenstrual Syndrome Medicine Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Premenstrual Syndrome Medicine Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Premenstrual Syndrome Medicine Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Premenstrual Syndrome Medicine Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Premenstrual Syndrome Medicine Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Premenstrual Syndrome Medicine Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Premenstrual Syndrome Medicine Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Asarina Pharma AB
  2. 8.1.1 Asarina Pharma AB Company Information
  3. 8.1.2 Asarina Pharma AB Business Overview
  4. 8.1.3 Asarina Pharma AB Premenstrual Syndrome Medicine Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Asarina Pharma AB Premenstrual Syndrome Medicine Product Portfolio
  6. 8.1.5 Asarina Pharma AB Recent Developments
  7. 8.2 Pherin Pharmaceuticals Inc
  8. 8.2.1 Pherin Pharmaceuticals Inc Company Information
  9. 8.2.2 Pherin Pharmaceuticals Inc Business Overview
  10. 8.2.3 Pherin Pharmaceuticals Inc Premenstrual Syndrome Medicine Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Pherin Pharmaceuticals Inc Premenstrual Syndrome Medicine Product Portfolio
  12. 8.2.5 Pherin Pharmaceuticals Inc Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Premenstrual Syndrome Medicine Value Chain Analysis
  2. 9.1.1 Premenstrual Syndrome Medicine Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Premenstrual Syndrome Medicine Sales Mode & Process
  6. 9.2 Premenstrual Syndrome Medicine Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Premenstrual Syndrome Medicine Distributors
  9. 9.2.3 Premenstrual Syndrome Medicine Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst